MGP抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09811(MGP Antibody) at dilution 1/75. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P09811(MGP Antibody) at dilution 1/75. (Original magnification: ×200)    

  
  

Matrix Gla Protein (MGP), a vitamin K-dependent protein, plays a critical role in inhibiting vascular calcification and soft tissue mineralization. First identified in the 1980s, MGP is synthesized in vascular smooth muscle cells, chondrocytes, and other tissues. Its function hinges on post-translational γ-carboxylation, a process requiring vitamin K, which enables MGP to bind calcium ions and prevent pathological mineralization. Deficiencies in MGP or its carboxylation are linked to cardiovascular diseases, chronic kidney disease, and rare genetic disorders like Keutel syndrome.

MGP antibodies, developed to detect and quantify this protein, are essential tools in studying its physiological and pathological roles. These antibodies target specific epitopes, including carboxylated (cMGP) or undercarboxylated (ucMGP) forms, enabling researchers to investigate MGP's involvement in vascular health, bone metabolism, and disease mechanisms. Commercial and custom MGP antibodies are widely used in immunoassays (ELISA, Western blot), immunohistochemistry, and flow cytometry. Recent studies also explore their diagnostic potential, as altered MGP levels correlate with cardiovascular risk and renal dysfunction. However, challenges persist in standardizing assays due to MGP's structural complexity and variability in post-translational modifications. Ongoing research aims to refine antibody specificity and develop therapeutic strategies targeting MGP pathways to combat calcification-related diseases.